Sun Pharmaceutical Industries Limited is the world’s fourth-largest specialty generic pharmaceutical company. It began in 1983 with just five psychiatry products. Now, it boasts a portfolio of over 2000 products and operates in over 100 countries.
Beyond its primary business, Sun Pharma demonstrates a commitment to social responsibility. Through its ‘Recycle to Rekindle’ initiative, the company repurposed 770 kgs of old clothing into rugs, which were then distributed among specially-abled children, tribal schools, and underprivileged communities across Maharashtra. Let’s cover here everything you need to know about Sun Pharma.
Sun Pharma Financials
In the financial year 2023, Sun Pharma’s sales reached Rs Rs 14,889.3 cr, with a net profit of Rs 9,576.38 cr. Its revenue from operations also hiked by 10.50%.
In terms of Sun Pharma Share Price movement, the returns over different time frames are as follows:
1-year: 57.95%
2-year: 74.80%
3-year: 115.78%
4-year: 224.79%
5-year: 244.16%
On the Sun Pharma Share Chart, you can see the 52 weeks range between Rs 1,638.85 to Rs 922.45. The price-to-equity ratio for this stock is 38, while the dividend yield ratio stands at 0.77%.
Sun Pharma vs Competition
1. Cipla
Cipla Limited has a history dating back to 1935 and operates across various therapeutic categories. For the financial year ending in March 2023, the company achieved a turnover of Rs 22,753 crore and a net income of Rs 2,835 crore.
During the same period, Cipla had total liabilities of Rs 29,463 crore. On the price chart, the one-year return is 41.84%, while over the last five years, it has generated a return of 141.12%.
2. Aurobindo Pharma
Aurobindo Pharma is another prominent name in the pharmaceutical sector. In FY23, the company generated sales of Rs 24,855 crore and a net income of Rs 1,928 crore. The total liabilities for the same period amounted to Rs 39,890 crore.
The PE ratio of this stock is 23, and the dividend yield is 0.67%. The one-year return of Aurobindo Pharma is 82.22%, while the five-year return stands at 50.69%.
3. Dr Reddy’s Laboratories
Dr Reddy’s turnover in FY23 amounted to Rs 24,670 crore, with a net profit of Rs 4,507 crore. The company’s current and non-current liabilities for the same period were Rs 8,572 crore and Rs 427 crore, respectively.
Regarding share price movement, the stock generated a 21.65% return in one year and 105.85% in five years.
The PE ratio of Dr Reddy’s Laboratories is 18, while the dividend yield is 0.68%.
4. Lupin
Lupin’s annual turnover for FY23 reached 16,642 crore, with a net profit of Rs 448 crore. Total liabilities for this period stood at Rs 22,956 crore.
Lupin’s share price surged by 114.42% in one year and 92.43% in the last five years. Lupin has a market capitalization of Rs Rs 72,202.20 crore. The company has a PE ratio of 38 and a dividend yield of 0.50%.
Conclusion
The Pharma sector holds immense potential. There is no significant difference between Sun Pharma and its competitors. Some offer better annual returns, while others boast stronger financials.
